

## PW01-14 - LITHIUM PLACENTAL PASSAGE AND PERINATAL OUTCOME: CLINICAL MANAGEMENT DURING LATE PREGNANCY

M.L. Imaz<sup>1</sup>, M. Torra<sup>2</sup>, C.C. Santos-Lozano<sup>1,3</sup>, A. Torres<sup>1</sup>, C. Marqueta<sup>4</sup>, J.M. Hernández<sup>5</sup>, J.M. Pérez<sup>6</sup>, I. Teixido<sup>7</sup>, R. Martín-Santos<sup>8,9,10</sup>, L. García-Esteve<sup>1,9</sup>

<sup>1</sup>Perinatal Psychiatry Programme, Institute Clinic of Neuroscience (ICN), Hospital Clínic-Maternitat,

<sup>2</sup>Biochemistry and Molecular Genetic, Biomedical Diagnostic Centre (CDB), Hospital Clínic, Barcelona,

Spain, <sup>3</sup>Psychiatry, Hospital Universitario UANL 'Dr. José E. González', Monterrey, Mexico, <sup>4</sup>Psychiatry,

Consorci Sanitari de Terrassa, Tarrasa, <sup>5</sup>Neonatal Screening, Biomedical Diagnostic Centre (CDB),

Hospital Clínic, <sup>6</sup>Neonatology, <sup>7</sup>Obstetric, Institute Clínic of Gynecology, Obstetric and Neonatology

(ICGON), Hospital Clínic-Maternitat, <sup>8</sup>Psychiatry, Institute Clínic of Neuroscience (ICN), Hospital Clínic,

<sup>9</sup>IDIBAPS, <sup>10</sup>CIBERSAM, Barcelona, Spain

**Introduction:** Despite lithium has been used for the last 50 years as a maintenance treatment for bipolar disorder during pregnancy, there is limited information about perinatal clinical outcomes from fetal exposure to lithium.

### Objectives:

1. To quantify the rate of lithium placental passage
2. To assess any association between plasma concentration of lithium at delivery and perinatal outcome.

**Methods:** Observational and prospective study. Subjects: Women in maintenance treatment with lithium, being attended during pregnancy at the Perinatal Psychiatry Programme of Hospital Clínic (Barcelona, Spain) between 2007 and 2009. Procedure: We assessed sociodemographical data; dose/day of lithium carbonate; other drugs doses; plasmatic concentration of lithium carbonate in maternal blood intrapartum and in the umbilical cord; obstetrical maternal complications; gestational age at delivery; weight at delivery; Apgar scores; congenital malformations; hospital stays, infant serum concentrations of thyroid-stimulating hormone.

**Results:** Eight mother-child diads. Mean age of the mother (SD): 32.1 (4,7); 100% caucasian and married. Mean dose of maternal lithium (SD): 675mg (237,5mg). Premature rupture of membranes (%):25. Gestational mean age (in weeks) (SD): 39,9 (1). Birth weight (SD) : 3625gr (451,2gr); Mean Apgar<sub>1min</sub> (SD): 8,38 (1,1); Mean Apgar<sub>5min</sub> (SD): 9,75 (0,4). Loss of fetal intrapartum wellness (%): 12,5. Days of hospitalization (mean) (SD):9,5(16,6). Lithium plasmatic concentration (mEq/L), mean (SD): maternal 0,45(0,1), umbilical cord 0,33(0,1), lithium ratio uc/m 0,93 (0,3); infant TSH  $\mu$ U/mL mean (SD): 4,9(4,6).

**Conclusions:** Lithium placental passage was 0,93 (0,63-1,07).  $\leq$ At umbilical cord lithium levels  $\leq$  0.60 mEq/L, we didn't have any preterm deliveries, low birth weight newborns, nor neonatal complications.